levonantradol

Levonantradol (CP 50,556-1) is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. It is a small molecule drug that acts as a full agonist at the CB1 and CB2 cannabinoid receptors. Approximately 30 times more potent than THC, levonantradol was investigated for its antiemetic and analgesic properties, specifically for the treatment of postoperative pain and chemotherapy-induced nausea and vomiting (CINV). Despite demonstrating efficacy in clinical trials, its development was discontinued due to a high incidence of dose-limiting psychotropic side effects, including dysphoria, sedation, and thought disturbances, and because it offered no significant therapeutic advantage over existing medications like codeine.